文献速递前列腺癌

64Cu-SAR-bisPSMA与68Ga-PSMA-11 PET/CT在前列腺癌根治术后生化复发中的前瞻性比较(Co-PSMA试验)

Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).
PubMed 文献 · Eur Urol · 2026-03-28

这项前瞻性影像试验纳入50例根治术后生化复发(PSA 0.2-0.75 ng/ml)患者,比较64Cu-SAR-bisPSMA与68Ga-PSMA-11 PET/CT的检出率。24小时64Cu-bisPSMA阳性率为78%(39/50),显著高于68Ga-PSMA的36%(18/50),且44%(22/50)患者管理发生改变。64Cu-bisPSMA的参考标准真阳性率为71%(24/34),假阴性率21%(7/34),优于68Ga-PSMA的29%和65%。

要点

  • 24小时64Cu-bisPSMA检出率78% vs 68Ga-PSMA 36%,差异显著。
  • 64Cu-bisPSMA导致44%患者管理改变,参考标准真阳性率71%。
  • 64Cu-bisPSMA假阴性率21%,低于68Ga-PSMA的65%。

核心结论

  • 64Cu-bisPSMA PET/CT在根治术后生化复发患者中检出的复发灶数量高于68Ga-PSMA PET/CT,且对管理有实质性影响,参考标准真阳性率高。

研究设计与样本

  • 前瞻性影像试验纳入50例根治术后生化复发患者,PSA范围0.2-0.75 ng/ml,在3周内完成64Cu-bisPSMA(1和24小时)及68Ga-PSMA PET/CT,前瞻性报告并三重读取一致性,评估管理影响。

主要发现

  • 人均病灶数64Cu-bisPSMA为1.26,68Ga-PSMA为0.48,差异0.78(95%CI: 0.52-1.04),比值2.63(95%CI: 1.64-4.20),p<0.0001。
  • 24小时64Cu-bisPSMA每人阳性率78%(39/50),68Ga-PSMA为36%(18/50)。
  • 两次扫描间管理改变者占44%(22/50)。
  • 64Cu-bisPSMA三重读取一致率84%(42/50),68Ga-PSMA为80%(40/50)。
  • 参考标准真阳性率64Cu-bisPSMA 71%(24/34)vs 68Ga-PSMA 29%(10/34);假阴性率分别为21%(7/34)和65%(22/34)。

关键数值与推荐

  • 主要终点为人均病灶差异,采用配对t检验和混合效应泊松回归分析。
  • 参考标准包括活检、靶向治疗反应(未用雄激素剥夺治疗)、观察或重复影像(64Cu-bisPSMA)中的PSA变化。

临床怎么用

  • 对于根治术后低PSA水平(0.2-0.75 ng/ml)的生化复发患者,64Cu-bisPSMA PET/CT可提高复发灶检出率并影响治疗决策。

局限性

  • 样本量较小(50例),参考标准不完整(34例可评估),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Prostate-specific membrane-antigen positron emission tomography (PSMA-PET) has transformed management of prostate cancer biochemical recurrence (BCR) with higher diagnostic accuracy than previous imaging modalities. 64Cu-SAR-bisPSMA PET/computed tomography (CT) (64Cu-bisPSMA) is a bivalent-PSMA-peptide with 12.7-hr half-life. The study objective was detection rate (per-patient) comparison between 64Cu-bisPSMA and 68GaPSMA-11 PET/CT (68Ga-PSMA) in BCR post radical prostatectomy (RP) (NCT06907641). METHODS: This prospective imaging trial enrolled 50 participants with BCR (PSA 0.2-0.75 ng/ml). 64Cu-bisPSMA (1 and 24 hr) and 68Ga-PSMA were acquired within 3-wk. Images were prospectively reported, and triple read for concordance. Management impact was evaluated after 68Ga-PSMA and 64Cu-bisPSMA. A reference standard (RS) for accuracy included biopsy, targeted treatment response (no androgen deprivation therapy), PSA increase/decrease on observation or repeat imaging (64Cu-bisPSMA). The primary endpoint was mean per-participant lesional difference. Paired t tests and mixed-effects Poisson regression assessed lesion number differences between scans. KEY FINDINGS AND LIMITATIONS: Median prostate specific antigen (PSA) was 0.43 (interquartile range: 0.31-0.63). Mean per-participant lesions were higher in 64Cu-bisPSMA (1.26) versus 68GaPSMA (0.48), difference 0.78 (95% CI: 0.52-1.04), ratio 2.63 (95% CI: 1.64-4.20) (p < 0.0001). At a per-participant level 78% (39/50) were positive on 24-hr 64Cu-bisPSMA compared to 36% (18/50) on 68GaPSMA. Management changed between scans in 22/50 (44%). 64Cu-bisPSMA were triple concordant in 84% (42/50) and 68Ga-PSMA reads in 80% (40/50). RS-true positive was 71% (24/34) versus 29% (10/34) and RS-false negative rate was 21% (7/34) versus 65% (22/34) for 64Cu-bisPSMA versus 68Ga-PSMA, respectively. CONCLUSION AND CLINICAL IMPLICATIONS: 64Cu-bisPSMA-PET/CT identifies a higher number of disease recurrences than 68Ga PSMA-PET/CT with substantial management impact and a high RS true positive rate in men with BCR post RP.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Khan S, Papa N, Kneebone A, et al. Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol. 2026. PMID: 41904043. doi:10.1016/j.eururo.2026.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。